ArticleEuropean neurological review2013
Autoimmune Encephalitis.
Article in European neurological review, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 82 citations in OpenAlex.
- Adjunctive Mediterranean Diet in a Middle-Aged Male With Autoimmune Encephalitis and Generalized Tonic-Clonic Seizures: A Longitudinal Case Report.Clinical case reports · 2026Article
- Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Current and Future Biomarkers in the Diagnosis of Autoimmune Encephalitis: A Review of Biomarker Detection Techniques and Their Performance.Medicina (Kaunas, Lithuania) · 2026Review
- Indications and Diagnostic Yield of Paraneoplastic and Autoimmune Encephalitis Antibody Testing: A Retrospective Cohort Study.Brain and behavior · 2025Article
- Approach and overview of autoimmune encephalitis: A review.Medicine · 2025Review
- Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.Journal of neurology · 2025Article
- Clinical features, cerebrospinal fluid changes, and prognosis in Chinese patients with autoimmune encephalitis.Acta neurologica Belgica · 2024Article
- Article
- Prognostic factors and treatment outcomes in pediatric autoimmune encephalitis: a multicenter study.Frontiers in neurology · 2024Article
- CSF Mitochondrial N-Formyl Methionine Peptide as Complementary Diagnostic Tool in Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis.Neuropsychiatric disease and treatment · 2024Article
- A complex case of young child with ADHD, developmental delay who developed seronegative autoimmune encephalitis exacerbated by stimulants.Brain, behavior, & immunity - health · 2023Article
- Antibody-Negative Autoimmune Encephalitis: A Single-Center Retrospective Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Article
- Strategies for the Emergency Treatment of Pregnant Women with Neurological Symptoms during the COVID-19 Pandemic.Aging and disease · 2023Article
- Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes.Drugs · 2023Review
- Teenager with acute psychosis due to non-paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis with a successful recovery: A case report.Annals of medicine and surgery (2012) · 2022Article
- Article
- Neuroimaging and CSF Findings in Patients with Autoimmune Encephalitis: A Report of Eight Cases in a Single Academic Center.Neurology international · 2022Article
- Acute cerebral atrophy in autoimmune encephalitis complicated by haemophagocytic lymphohistiocytosis.BMJ case reports · 2021Article
- Longitudinal CSF Findings in Autoimmune Encephalitis-A Monocentric Cohort Study.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
The term autoimmune encephalitis is used to describe a group of disorders characterised by symptoms of limbic and extra-limbic dysfunction occurring in association with antibodies against synaptic antigens and proteins localised on the neuronal cell surface. In recent years there has been a rapidly expanding knowledge of these syndromes resulting in a shift in clinical paradigms and new insights into pathogenic mechanisms. Since many patients respond well to immunosuppressive treatment, the recognition of these disorders is of utmost importance. In general, there are no brain-imaging modalities or biomarkers specific of these disorders other than the demonstration of the neuronal antibodies. A disease classification based on these antibodies provides information on prognosis and paraneoplastic aetiology. This article focuses on recent clinical advances, newly characterised antibodies and treatment approaches to these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.